{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-21-307134","form_type":"8-K","ticker":"BBIO","cik":"0001743881","company_name":"BridgeBio Pharma, Inc.","filed_at":"2021-10-26T23:59:59+00:00","discovered_at":"2026-05-14T18:04:13.912536+00:00","generated_at":"2026-06-28T18:05:28.789100+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"BridgeBio expands board to 15, appoints Dr. Hannah Valantine as director effective Oct 23, 2021","bullets":["Board of Directors expanded from 14 to 15 members; Dr. Hannah Valantine appointed as Class I director effective Oct 23, 2021.","Dr. Valantine received option to purchase $1,200,000 of common stock at $48.45 per share, vesting over three years.","She currently serves as Professor of Medicine at Stanford and was former Chief Officer for Scientific Workforce Diversity at NIH (2014-2020).","Dr. Valantine co-invented organ donor-derived cell-free DNA technology for transplant rejection monitoring.","She also serves on boards of Pacific Biosciences (PACB) and CareDx (CDNA)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-21-307134","json":"https://secwatch.observer/filing/0001193125-21-307134.json","markdown":"https://secwatch.observer/filing/0001193125-21-307134.md","text":"https://secwatch.observer/filing/0001193125-21-307134.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1743881/000119312521307134/0001193125-21-307134-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1743881/000119312521307134/d164687d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T18:05:28.789100+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c48fa923bd","claim":"Dr. Hannah A. Valantine was appointed as Director at BridgeBio Pharma, Inc..","evidence_excerpt":"Effective as of October 23, 2021, the Board, upon the recommendation of the Nominating and Corporate Governance Committee, appointed Dr. Hannah A. Valantine to the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1743881/000119312521307134/0001193125-21-307134-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}